Safety and Efficacy of Amyloid-Beta Directed Antibody Therapy in Mild Cognitive Impairment and Dementia with Evidence of Lewy Body Dementia and Amyloid-Beta Pathology (U01 - Clinical Trial Required)

Federal funding opportunity RFA-NS-25-010 from National Institutes of Health (Department of Health and Human Services).

Program funding history

Synopsis

Who can apply

• Small businesses
• Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
• Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
• Public housing authorities/Indian housing authorities
• Private institutions of higher education
• Public and State controlled institutions of higher education
• Native American tribal organizations (other than Federally recognized tribal governments)
• County governments
• Special district governments
• Independent school districts
• For profit organizations other than small businesses
• State governments
• City or township governments
• Others (see text field entitled "Additional Information on Eligibility" for clarification)
• Native American tribal governments (Federally recognized)

Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.

The official record

Similar grants

• Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Neurotherapeutic Agent Characterization and In vivo Efficacy Studies (R61/R33 Clinical Trial Not Allowed)
  PAR-25-225 · National Institutes of Health · closes October 20, 2027
• Translational Bioinformatics and Experimental Approaches to Advance Drug Repositioning and Combination Therapy Development for Alzheimers Disease and Related Dementias (R01 Clinical Trial Not Allowed)
  PAR-25-374 · National Institutes of Health · closes May 7, 2028
• NINDS Efficacy and Exploratory Clinical Trials (UG3/UH3 - Clinical Trial Required)
  PAR-27-065 · National Institutes of Health · closes March 9, 2029
• Early- and Late-Stage Clinical Trials for the Spectrum of Alzheimer's Disease/Alzheimer's Disease-Related Dementias and Age-Related Cognitive Decline
  FOR-RFA-AG-26-020 · National Institutes of Health
• Biomarkers of Cognitive Decline and Dementias of Aging in Individuals within the Autism Spectrum
  FOR-TEMP-25653 · National Institutes of Health
• Dementia Care and Caregiver Support Intervention Research - Stage I Only
  FOR-TEMP-28923 · National Institutes of Health